Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

3 Magnificent Growth Stocks to Buy in March


It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked three Motley Fool contributors to pick slam-dunk growth stocks investors can confidently add to their portfolios. They chose three famous drugmakers: Eli Lilly (NYSE: LLY), Amgen (NASDAQ: AMGN), and Vertex Pharmaceuticals (NASDAQ: VRTX). Read on to discover why.

Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry. For pharmaceutical companies, especially those with a market cap above $50 billion, year-over-year top-line increases in the high-single-digit percentages are already pretty strong. With that context in mind, consider that Eli Lilly's revenue growth has not dipped below 20% since mid-2023.

LLY Operating Revenue (Quarterly YoY Growth) Chart

Continue reading


Source Fool.com

Amgen Inc. Stock

€250.55
-1.570%
We can see a decrease in the price for Amgen Inc.. Compared to yesterday it has lost -€4.000 (-1.570%).
With 24 Buy predictions and 4 Sell predictions Amgen Inc. is one of the favorites of our community.
As a result the target price of 308 € shows a positive potential of 22.93% compared to the current price of 250.55 € for Amgen Inc..
Like: 0
LLY
Share

Comments